A review of medications used for treatment of obesity

• Authors: Anna CZOPEK , Agnieszka ZAGÓRSKA , Maciej PAWŁOWSKI

Title variants

PL

Przegląd najważniejszych preparatów stosowanych w leczeniu otyłości

• Languages of publication: PL

Abstracts

EN

Obesity, which occurs both in rich as well as developing countries, is a chronic disease that can cause many serious illnesses. It has become a global health problem, which affects onethird of adult population in the world. To induce weight loss, profound lifestyle modification is required. In the case, when lifestyle changes alone are insufficient, pharmacotherapy can be helpful. Most of anti-obesity drugs (e. g. fenfluramine, sibutramine, rimonabant), which have been approved for treatment of obesity, were subsequently withdrawn from the market due to their adverse effects. In this manuscript, a short overview of currently available anti-obesity drugs like orlistat, lorcaserin, liragutide as well as phentermine/topiramate and naltrexone/ bupropion combination, was presented. Herein we focus on efficiency, mechanism of action and possible side effects of anti-obesity drugs. Finally, it was emphasized that better understanding of mechanisms involved in appetite regulation could be useful for developing novel, more effective and better tolerated anti-obesity drugs.

Keywords

EN

"obesity pharmacotherapy; "overweight"; obesity"

Discipline

• MEDICINE: MEDICINE

• Journal: Medicina Internacia Revuo
• Year: 2016
• Volume: 27
• Issue: 106
• Pages: 20-25

Contributors

author

Anna CZOPEK

• Katedra Chemii Farmaceutycznej, Uniwersytet Jagielloński Collegium Medicum, ul. Medyczna 9, 30-688 Kraków

author

Agnieszka ZAGÓRSKA

• Katedra Chemii Farmaceutycznej, Uniwersytet Jagielloński Collegium Medicum, ul. Medyczna 9, 30-688 Kraków

author

Maciej PAWŁOWSKI

• Katedra Chemii Farmaceutycznej, Uniwersytet Jagielloński Collegium Medicum, ul. Medyczna 9, 30-688 Kraków

References

• 1. Zahorska­Markiewicz, B.;. Post. N. Med. 2009, 7, 494­497.
• 2. Ng, M.; Fleming, T.; Robinson, M.; Thomson, B.; Graetz, N.; Margono, C. et al.;. Lancet 2014, 384, 766­781.
• 3. Partyka, A.; Jastrzębska­Więsek, M.; Wróbel, D.; Wesołowska, A.;. Czas. Aptek. 2012, 44(2), 38­46.
• 4. Daubresse, M., Alexander, G.C.; Int. J. Obes. (Lond). 2015, 39(3), 377­378.
• 5. Kakkar, A.K.; Dahiya, N.;. Eur. J. Intern. Med. 2015, 26(2), 89­94.
• 6. Gogga, P.; Karbowska, J.; Meissner, W.; Kochan, Z.;. Postępy Hig. Med. Dośw. 2011, 65, 255­262.
• 7. Nylec, M.; Olszanecka­Glinianowicz, M.;. Postępy Hig. Med. Dośw. 2010, 64, 291­295.
• 8. Korek, E.; Krauss, H.; Piątek, J.; Checińska, Z.;.Med. Ogólna Nauki Zdr. 2013, 19(2), 211­217.
• 9. Kostulski, A.; Rebe­Jabłońska, J.;. Psychiatr. Psychol. Klin. 2007, 7(2), 108­116.
• 10. Fijałkowski, F., Jarzyna, R.; Postepy Hig. Med. Dosw. 2010, 64, 231­243.
• 1. Kusz­Rynkun, A.; Walicka, M.; MarcinowskaSuchowierska, E.;. Post. N. Med. 2013, 5, 44­48.
• 12. Cheung B.M.Y.; Cheung, T.T.; Samaranayake N.R.;. Ther. Adv. Drug Saf. 2013, 4(4) 171­181.
• 13. Bray, G.A.;. Best Pract. Res. Clin. Gastroenterol. 2014, 28(4), 665­684.
• 14. Kim, G.W., Lin, J.E., Blomain, E.S., Waldman, S.A.; Clin. Pharmacol. Ther. 2014, 95(1), 53­66.
• 15. Rodgers, R.J. Tschöp, M.H., Wilding, J.P.; Dis. Model. Mech. 2012, 5(5), 621­626.
• 16. Anghelescu, I., Klawe, C., Benkert, O.: J. Clin. Psychopharmacol. 2000, 20(6), 716­7.
• 17. Hainer, V.; Expert Opin. Pharmacother. 2014, 15(14), 1975­1978.
• 18. Shyh, G., Cheng­Lai, A.; Cardiol. Rev. 2014, 22(1), 43­50.
• 19. Zięba, R.;. Postępy Hig. Med. Dośw. 2007, 61, 612626.
• 20. Butsch, W.S.;. Curr. Opin. Endocrinol. Diabetes Obes. 2015, 22(5), 360­366.
• 21. Pucci, A.; Finer, N.;. Can. J. Cardiol. 2015, 31(2), 142­152.
• 22. Med. Lett. Drugs Ther. 2015, 57(1471), 89­9.
• 23. Toplak, H., Woodward, E., Yumuk, V., Oppert, J., Halford, J.C.G., Frühbeck, G.; Obes. Facts, 2015, 8, 166­174.
• 24. Billes, S.K., Sinnayah, P., Cowley, M.A.; Pharmacol. Res. 2014, 84, 1­11.

• Document Type: review